FR3110166B1 - Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l’hepatite c et l’hepatite b - Google Patents
Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l’hepatite c et l’hepatite b Download PDFInfo
- Publication number
- FR3110166B1 FR3110166B1 FR2004848A FR2004848A FR3110166B1 FR 3110166 B1 FR3110166 B1 FR 3110166B1 FR 2004848 A FR2004848 A FR 2004848A FR 2004848 A FR2004848 A FR 2004848A FR 3110166 B1 FR3110166 B1 FR 3110166B1
- Authority
- FR
- France
- Prior art keywords
- hepatitis
- immunogenic compositions
- preparation
- new immunogenic
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 208000006454 hepatitis Diseases 0.000 title abstract 4
- 231100000283 hepatitis Toxicity 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 abstract 3
- 241000711549 Hepacivirus C Species 0.000 abstract 2
- 241000700721 Hepatitis B virus Species 0.000 abstract 2
- 208000005176 Hepatitis C Diseases 0.000 abstract 2
- 208000002672 hepatitis B Diseases 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 1
- 238000009117 preventive therapy Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24223—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
TITRE : NOUVELLES COMPOSITIONS IMMUNOGENES ET LEUR APPLICATION POUR LA PREPARATION DE VACCINS CONTRE L’HEPATITE C ET L’HEPATITE B L’invention a pour objet de nouvelles compositions immunogènes comprenant un mélange de particules d’enveloppes sous-virales chimères entre les protéines d’enveloppe du virus de l’hépatite B (HBV, pour Hepatitis B virus) et du virus de l’hépatite C (HCV, pour Hepatitis C virus). L’invention a également pour objet l’utilisation de ces nouvelles compositions immunogènes, en tant que vaccin, pour la prévention et/ou le traitement prophylactique et/ou thérapeutique de l’hépatite C, ou pour la prévention et/ou le traitement prophylactique et/ou thérapeutique de l’hépatite B, ou pour la prévention et/ou le traitement prophylactique et/ou thérapeutique de l’hépatite C et de l’hépatite B. Pas de figure
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2004848A FR3110166B1 (fr) | 2020-05-15 | 2020-05-15 | Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l’hepatite c et l’hepatite b |
PCT/EP2021/062853 WO2021229065A1 (fr) | 2020-05-15 | 2021-05-14 | Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l'hepatite c et l'hepatite b |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2004848 | 2020-05-15 | ||
FR2004848A FR3110166B1 (fr) | 2020-05-15 | 2020-05-15 | Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l’hepatite c et l’hepatite b |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3110166A1 FR3110166A1 (fr) | 2021-11-19 |
FR3110166B1 true FR3110166B1 (fr) | 2022-04-29 |
Family
ID=73038024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR2004848A Expired - Fee Related FR3110166B1 (fr) | 2020-05-15 | 2020-05-15 | Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l’hepatite c et l’hepatite b |
Country Status (2)
Country | Link |
---|---|
FR (1) | FR3110166B1 (fr) |
WO (1) | WO2021229065A1 (fr) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6740323B1 (en) * | 1999-11-24 | 2004-05-25 | Chiron Corporation | HBV/HCV virus-like particle |
AUPQ912000A0 (en) * | 2000-07-31 | 2000-08-24 | Crown In The Right Of The Queensland Department Of Health, The | Improved virus like particles |
FR2932388B1 (fr) * | 2008-06-17 | 2013-03-29 | Univ Rabelais Francois | Nouvelles proteines de fusion et leur application pour la preparation de vaccins contre l'hepatite c |
-
2020
- 2020-05-15 FR FR2004848A patent/FR3110166B1/fr not_active Expired - Fee Related
-
2021
- 2021-05-14 WO PCT/EP2021/062853 patent/WO2021229065A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2021229065A1 (fr) | 2021-11-18 |
FR3110166A1 (fr) | 2021-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rawat et al. | COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies | |
Jain et al. | Formulation and stabilization of recombinant protein based virus-like particle vaccines | |
Roy et al. | Virus‑like particles as a vaccine delivery system: Myths and facts | |
Velasquez et al. | Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine | |
HK1074578A1 (en) | Packaged virus-like particles in combination with cpg for use as adjuvants with allergens: method of preparation and use | |
Tumban et al. | Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2 | |
Zhang et al. | Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis | |
CN115190911B (zh) | 对sars冠状病毒2具有免疫原性的组合物、其制备方法和用途 | |
JP2011057692A (ja) | ウエストナイルワクチン | |
Budimir et al. | Heterosubtypic cross‐protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration | |
JP2018038405A (ja) | 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド | |
MX2023007395A (es) | Vacunas del virus de la peste porcina africana (ppa). | |
Liu et al. | Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines | |
RU2008114841A (ru) | Фармацевтическая композиция, способная индуцировать защитный иммунный ответ против вируса денге, содержащая капсидный белок этого вируса | |
Zhao et al. | Evaluation of aqueous extracts of Cistanche deserticola as a polysaccharide adjuvant for seasonal influenza vaccine in young adult mice | |
Cai et al. | Enhanced immune responses to E2 protein and DNA formulated with ISA 61 VG administered as a DNA prime–protein boost regimen against bovine viral diarrhea virus | |
WO2003066094A2 (fr) | Nouveau vaccin | |
US7374766B1 (en) | Compositions containing virus-like particles as immunopotentiators administered through the mucosa | |
FR3110166B1 (fr) | Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l’hepatite c et l’hepatite b | |
Silveira et al. | Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice | |
ES379642A1 (es) | Procedimiento para la obtencion de vacunas perfeccionadas. | |
Farnós et al. | The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice | |
WO2005016246A3 (fr) | Particules virales modifiees possedant des proprietes immunogenes et une teneur limitee en lipides utiles pour traiter et prevenir des maladies infectieuses | |
JP2016514114A5 (fr) | ||
Sacherl et al. | Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20211119 |
|
PLFP | Fee payment |
Year of fee payment: 3 |
|
ST | Notification of lapse |
Effective date: 20240105 |